Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Zhang XD, et al. Among authors: mulligan g. Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28. Cancer Cell. 2016. PMID: 27132469 Free PMC article.
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Shah JJ, et al. Among authors: mulligan g. Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11. Clin Cancer Res. 2016. PMID: 26561559 Free PMC article. Clinical Trial.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mulligan G, et al. Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11. Blood. 2014. PMID: 24335104 Free PMC article. Clinical Trial.
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. Zhan F, et al. Among authors: mulligan g. Blood. 2008 Jan 15;111(2):968-9. doi: 10.1182/blood-2007-10-119321. Blood. 2008. PMID: 18182586 Free PMC article. No abstract available.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Keats JJ, et al. Among authors: mulligan g. Cancer Cell. 2007 Aug;12(2):131-44. doi: 10.1016/j.ccr.2007.07.003. Cancer Cell. 2007. PMID: 17692805 Free PMC article.
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Chng WJ, et al. Among authors: mulligan g. Cancer Res. 2007 Apr 1;67(7):2982-9. doi: 10.1158/0008-5472.CAN-06-4046. Cancer Res. 2007. PMID: 17409404 Clinical Trial.
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC. Lichter DI, et al. Among authors: mulligan g. Blood. 2012 Nov 29;120(23):4513-6. doi: 10.1182/blood-2012-05-426924. Epub 2012 Sep 27. Blood. 2012. PMID: 23018640 Free PMC article. Clinical Trial.
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, Garelli E, Mancini C, Lemmens H, Delforge M, Vandenberghe P, Wlodarska I, Aspesi A, Michaux L, Vanderkerken K, Sonneveld P, De Keersmaecker K. Hofman IJF, et al. Among authors: mulligan g. Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2. Leukemia. 2017. PMID: 27909306 Free PMC article.
An historic perspective of proteasome inhibition.
Esseltine DL, Mulligan G. Esseltine DL, et al. Among authors: mulligan g. Semin Hematol. 2012 Jul;49(3):196-206. doi: 10.1053/j.seminhematol.2012.04.009. Semin Hematol. 2012. PMID: 22726542 Review.
89 results